Gene ther­a­py goes acoustic as ARCH-backed biotech launch­es with ul­tra­sound gene de­liv­ery plat­form

Af­ter co-found­ing two biotechs off virus-based ther­a­pies, one for pain and one for can­cer, Ken Green­berg de­cid­ed to go in a dif­fer­ent di­rec­tion for his newest biotech, SonoThera.

Based out of San Fran­cis­co, SonoThera an­nounced Mon­day morn­ing that it raised $60.75 mil­lion to de­vel­op new gene ther­a­pies — but de­liv­ered by ul­tra­sound, which Green­berg says can ad­dress the ma­jor chal­lenges fac­ing more con­ven­tion­al vi­ral gene ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER